Final results from the VISTA trial demonstrate that the addition of Velcade® (bortezomib) to melphalan and prednisone substantially improves overall survival among patients with previously untreated multiple myeloma. These results were presented at the 53rd Annual Meeting of the American Society of Hematology. Multiple myeloma is a cancer of plasma cells. Plasma cells are a [...]
According to a study presented at the 2011 European Multidisciplinary Cancer Congress, children born to women who received chemotherapy during pregnancy do not appear to have an increased risk of heart or cognitive problems. Since relatively few women are diagnosed with cancer during pregnancy, data regarding the effects of chemotherapy during pregnancy are limited. Determining [...]
A large proportion of cancer patients do not enroll in clinical trials, and those who do participate may not adequately represent age groups, cancer stages, cancer types, and racial and ethnic groups. These findings were recently reported in the Annals of Surgery. Clinical trials are the process through which medications ultimately become approved by the [...]
Among older patients with newly diagnosed multiple myeloma, treatment with Revlimid® (lenalidomide) in combination with melphalan and prednisone, followed by Revlimid maintenance therapy (MPR-R) may result in better progression-free survival than two other treatment combinations. These interim results from an ongoing Phase III clinical trial were presented at the 52nd annual meeting of the American [...]
It appears that treatment of patients with newly diagnosed multiple myeloma with Zometa® (zoledronic acid) may improve overall survival and progression-free survival. These findings were recently reported in The Lancet. Multiple myeloma is a cancer of plasma cells, which are a special type of white blood cell that are part of the body’s immune system. [...]
Maintenance therapy with Revlimid® (lenalidomide) reduced the risk of myeloma progression or death by 60% among patients who had undergone an autologous stem cell transplant. These updated results from a Phase III clinical trial were presented at the 52nd annual meeting of the American Society of Hematology. Multiple myeloma is a cancer of plasma cells, [...]
Among patients with symptomatic newly diagnosed multiple myeloma, treatment with a combination of Revlimid® (lenalidomide), Velcade® (bortezomib), and dexamethasone produced a partial response or better in 100% of patients. The results of this Phase I/II clinical trial were published in the journal Blood. Multiple myeloma is a cancer of plasma cells, which are a special [...]
Among patients with newly diagnosed multiple myeloma (MM) who are ineligible for high-dose therapy and stem cell transplant, treatment with a combination of Velcade® (bortezomib), melphalan, prednisone, and thalidomide followed by maintenance therapy with Velcade and thalidomide (VMPT-VT) resulted in better response rate and progression-free survival than treatment with Velcade, melphalan, and prednisone (VMP) without [...]
Among patients with multiple myeloma or bone metastases from breast cancer, prostate cancer, or other solid tumors, denosumab was more effective than Zometa® (zoledronic acid) at delaying or preventing bone complications such as fracture. Results from an integrated analysis of Phase III clinical trials were presented at the 35th European Society for Medical Oncology (ESMO) [...]
Among multiple myeloma patients who have had an autologous stem cell transplant, additional treatment with Revlimid® (lenalidomide) delays cancer progression. These results were released by the National Cancer Institute. Multiple myeloma is a cancer of plasma cells. Plasma cells are a special type of white blood cell that are part of the body’s immune system. [...]
